Innoviva (INVA) Enterprise Value (2010 - 2026)
Innoviva's (INVA) quarterly Enterprise Value came in at -$603.1 million in Q1 2026, down 89.0% YoY from -$5.5 billion in Q1 2025, and down 9.46% on a QoQ basis from -$550.9 million in Q4 2025.
Innoviva (INVA) Enterprise Value (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Enterprise Value data on file, last reported at -$603.1 million in Q1 2026.
- Quarterly Enterprise Value fell 89.0% year-over-year to -$603.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$603.1 million (down 89.0% YoY) and the FY2025 annual result came in at -$550.9 million, down 80.66% from the prior year.
- Enterprise Value declined to -$603.1 million in Q1 2026, from -$550.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$144.0 million in Q1 2023 to a low of -$603.1 million in Q1 2026.
- A 5-year average of -$299.5 million and a median of -$283.6 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 1469.95% — and 2023, when it jumped 40.21%.
- Tracing INVA's Enterprise Value over 5 years: stood at -$291.0 million in 2022, then surged by 33.51% to -$193.5 million in 2023, then plunged by 57.59% to -$305.0 million in 2024, then sank by 80.66% to -$550.9 million in 2025, then retreated by 9.46% to -$603.1 million in 2026.
- The last three Enterprise Value figures came in at -$603.1 million (Q1 2026), -$550.9 million (Q4 2025), and -$476.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -570.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -570.39 Mn |
| Mar 31, 2026 | -603.09 Mn |
| Dec 31, 2025 | -550.94 Mn |
| Sep 30, 2025 | -476.51 Mn |
| Jun 30, 2025 | -397.53 Mn |
| Mar 31, 2025 | -319.09 Mn |
| Dec 31, 2024 | -304.96 Mn |
| Sep 30, 2024 | -260.63 Mn |
| Jun 30, 2024 | -217.00 Mn |
| Mar 31, 2024 | -178.36 Mn |
| Dec 31, 2023 | -193.51 Mn |
| Sep 30, 2023 | -180.00 Mn |
| Jun 30, 2023 | -173.03 Mn |
| Mar 31, 2023 | -144.05 Mn |
| Dec 31, 2022 | -291.05 Mn |
| Sep 30, 2022 | -301.07 Mn |
| Jun 30, 2022 | -283.58 Mn |
| Mar 31, 2022 | -216.80 Mn |
| Dec 31, 2021 | -90.33 Mn |
| Sep 30, 2021 | -46.12 Mn |